Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis' Competing Venture Funds Pursue Lower-Cost Innovation

This article was originally published in Start Up

Executive Summary

As biotech deal prices skyrocket, pharma's trying to get in on the ground floor, hoping for a bargain. But innovation-for-less is tough to engineer, and not everyone agrees on how it can be nurtured--and who is best placed to do the nurturing. Novartis now has two competing groups pursuing lower-cost venture-based paths to innovation. Neither, apparently, wants much to do with the other.

You may also be interested in...



Corporate Biotech Incubators

Corporate incubators at Pfizer and Biogen--designed to provide a supply of strategically aligned biotech assets to the parent pipeline--remain unproven. But they're among a range of experiments aimed at helping seed discovery-stage ventures

Corporate Biotech Incubators

Corporate incubators at Pfizer and Biogen--designed to provide a supply of strategically aligned biotech assets to the parent pipeline--remain unproven. But they're among a range of experiments aimed at helping seed discovery-stage ventures

Best of the Blog: Start-Up May 2008

In May, Windhover's editorial staff posted 35 articles to the blog, covering biopharma, device and diagnostics R&D, business development, regulatory and commercial news. Here are a few of our favorite SU oriented blog posts that didn't make it into stories covered elsewhere in this month's magazine: SR One 2.0?, BMS Gets KAI Heart Attack Compound Pumping, and Covidien Takes Small Bites.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL1128165

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel